

Correction

Our article *Nanomedicines – what are they?* (DTB 2011; 49: 58-60) reported that medicines containing nanoparticles available in the EU include oral suspensions of aprepitant (Emend) and sirolimus (Rapamune). The source of this information was a European Medicines Agency document, stating that medicinal products containing nanoparticles in the form of “suspensions (i.e. Rapamune, Emend) have already been granted Marketing Authorisations within the Community under the existing regulatory framework”.¹ We have since learned that there are no oral suspension formulations of these drugs marketed in the EU.

1. Committee for Medicinal Products for Human Use, 2006. *Reflection paper on nanotechnology-based medicinal products for human use* [online]. Available: http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2010/01/WC500069728.pdf [Accessed 26 August 2011].

DOI: 10.1136/dtb.2011.02.0057